INTRODUCTION
Pain is common in cancer patients, particularly in the advanced stage of disease when the prevalence is estimated to be more than 70% [1] . Adequate pain control is achieved in most patients with available analgesic therapies [2] .
However, despite adequate pain control for most hours of the day, patients may develop transient flares of pain throughout the day. This phenomenon is known as breakthrough cancer pain (BTP) [3] . BTP has been reported to produce a negative impact on quality of life and is associated with a significant physical, psychological, and economic burden [4] . Several studies have assessed the epidemiology of this phenomenon, reporting largely variable data in different settings by using different definitions and methodologies, e.g., without an a priori definition of BTP, without clearly distinguishing background pain intensity and BTP intensity, or without considering the level of opioids used for background analgesia [5] [6] [7] .
In recent years, BTP has been more meaningfully characterized through a diagnostic algorithm. Moreover, some attempts to better characterize this phenomenon according to a number of variables have been made. Recently, an expert consensus suggested that a BTP subclassification according to the characteristics of BTP may provide tailored treatment [8] .
In the previous Italian Oncologic Pain multiSetting (IOPS) study, performed in various settings in a large number of patients, several factors influencing the development and characteristics of BTP were assessed [9] . From this data, the IOPS expert group planned a new multicenter survey, with the aim of providing further information on BTP and the factors influencing its characteristics in a large number of patients, diagnosed according to a specific algorithm. The use of BTP medications and factors interfering with administration of transmucosal opioids, commonly used for the management of BTP because their PK profile fits with BTP onset and duration, were also evaluated [5] . Reported here is a preliminary analysis of data from the first 1500 patients of 
METHODS
This preliminary analysis included the first 1500 patients recruited in a national, observational, multicenter Italian study. An investigator meeting was held to present and comment on the project with the representatives of each center that participated. Subsequently, each center received an IOPS Multicentric Survey (IOPS-MS) investigator manual.
Thirty-two centers were involved. Each center consecutively enrolled patients for 24 months after obtaining local ethic committee approval and the patients' informed consent. Patients were recruited in the most common care settings where cancer patients are assessed for pain, including oncology, outpatient pain therapy, palliative care, and radiotherapy settings. The place of assessment was also recorded, including outpatient clinic, day hospital, home care, hospice, and inpatient ward.
Inclusion criteria were age greater than 18 years, cancer diagnosis at any stage, stable background pain in the last week with an intensity of at most 4 on a numerical scale from 0 to 10, and episodes of BTP with an intensity of 5 or more, clearly distinguished from background pain.
A standard algorithm to diagnose BTP was followed according to the following definition:
BTP is a transitory exacerbation of pain of moderate to severe intensity that occurs spontaneously or predictably [8] [9] [10] [11] , and is well distinguished from background pain of mild intensity [6, 12] . Exclusion criteria were the absence of a cancer diagnosis, uncontrolled background pain ([4 on a numerical scale of 0 to 10), or no relevant increases in pain intensity (\5) which could be interpreted as BTP episodes. Patients were also questioned about BTP predictability, BTP onset (B10 or [10 min), BTP duration, background and BTP medications and their doses, time to meaningful pain relief after BTP medication, and satisfaction with BTP medication (a four-point scale was used by physicians: very satisfied, satisfied, not satisfied, and neither satisfied nor dissatisfied) [9, 10] . The occurrence of adverse reactions was also assessed, and mucosal toxicity was graded according to the World Health Organization (WHO) criteria [13] . The presence of candidiasis and xerostomia was also recorded. Each patient followed local policy and therapeutic protocols, and no specific treatment for BTP was assigned. To guarantee good quality of the data, these were entered in a web-based clinical report form. Each center had an individual password to enter their data into the system, and the study monitors could check records by local and remote monitoring.
Statistics
Data from the first 1500 patients were preliminarily examined. Continuous variables were summarized as means and standard deviations (SD 
RESULTS

Patient Characteristics
Of the first 1500 patients recruited in IOPS-MS, most had metastatic disease and were receiving anticancer treatment ( p\0.001).
BTP Characteristics
The initial diagnosis of BTP was most often performed by oncologists (n = 616 diagnoses, 41%) and pain physicians (n = 583, 39%), followed by palliative care physicians (n = 241, 16%), nurses (n = 18, 1%), general practitioners (n = 15, 1%), other healthcare providers (n = 15, 1%), and radiotherapists (n = 9, 0.6%). In three cases, data were unavailable. The distribution of BTP mechanisms in the different care settings is reported in Table 3 . A mixed mechanism of BTP was found to be more represented in oncology and pain therapy settings than in radiotherapy and palliative care settings. Conversely, a nociceptive mechanism was more frequently found in palliative care and radiotherapy settings than in oncology and pain therapy settings.
Predictable BTP
BTP was unpredictable in 977 patients (65.1%) and predictable in 523 patients (34.9%).
Predictable BTP was associated with age (p = 0.008), pain mechanism (p\0.001, lower risk with mixed mechanism), place of assessment (p\0.001), care setting (p = 0.002), background pain (p = 0.004), diagnosis of prostate cancer (p = 0.030), Karnofsky index (p = 0.046), and oral mucositis (p\0.001). In (n = 349, 67%), followed by swallowing (n = 80, 15%), cough (n = 54, 10%), procedure (n = 39, 7%), and bowel movement (n = 31, 6%).
Intensity of Background Pain and BTP
The mean intensity of background pain on assessment and the average pain in the previous week were both 3.0 ± 1.1. The mean doses of oral morphine equivalents (OME) used for background pain were 69.8 ± 139.7 mg/day.
The mean intensity of BTP was 7.5 ± 1.4.
Rapid-onset BTP and high levels of background pain intensity were associated with a higher BTP intensity. Conversely, a slow-onset BTP was associated with a lower BTP intensity. No differences in BTP intensity among the care settings and triggers of predictable BTP were found. Using mixed pain mechanism as a reference, BTP intensity was higher for neuropathic pain (p = 0.0248) and lower for nociceptive pain (p = 0.0257). BTP was of lower intensity in older patients (p = 0.0002), in patients with higher Karnofsky status (p = 0.0016), and in patients with breast cancer (p = 0.04). Finally, mucositis was associated with higher BTP intensity (p = 0.0083).
BTP Medications
A total of 1263 (84%) patients were receiving opioid drugs for the management of BTP, including fentanyl pectin nasal spray (FPNS, 
Time to Meaningful Pain Relief After Drug Administration
The mean time for achieving meaningful pain relief after BTP medication was 17 ± 14 min. In Table 4 , the variables associated with the time (Table 5) .
Adverse Effects of BTP Medications
Adverse reactions attributed to BTP medications were reported in 53 out of 1500 (4%) patients and were constipation (n = 18), dizziness (n = 18), nausea (n = 5), headache (n = 2), vomiting (n = 1), and other unspecified adverse effects (n = 9). The intensity was mild in 46 patients (88%) and moderate in 6 patients (12%). In 38 patients (83%) no specific therapeutic change was required, while in the remaining 8 cases (17%) it was deemed necessary to treat the adverse effects or discontinue the BTP medication. No association was found between adverse reactions and choice and dosage of opioids used for BTP (p = 0.843). Finally, no medication abuse was reported.
Oral Mucositis
Two hundred and twelve patients (14%) presented with different levels of oral 
DISCUSSION
Preliminary data for the first 1500 patients of the IOPS-MS survey suggest that, in general, in patients with BTP, older patients and patients with a lower Karnofsky index were most frequently followed in a palliative care setting. This information is consistent with data collected in the previous IOPS survey [9] and in other surveys performed either in oncology or in palliative care settings [14, 15] , confirming that the patients' characteristics differ among the settings of care, particularly in patients with the highest morbidity under the care of palliative care physicians. Data suggest that higher prevalence rates of BTP are reported in studies performed in the hospice setting [9, 16, 17] .
Results of this survey suggest that the diagnosis of BTP was performed more frequently by oncologists than by palliative care physicians. Conversely, a longer time for diagnosis of BTP was reported in the hospice setting. Oncologists generally have more opportunities to make an early diagnosis of BTP, as they see patients more often through the course of disease [18] , whereas physicians in palliative care see patients later in the course of their disease, which may explain this result. Another explanation could be that oncologists argue that the management of background pain of these patients could be better optimized. This observation confirms previous data, in which very advanced and bedridden patients had fewer BTP episodes with longer onset [9] . The mean duration of untreated BTP was about 40 min, reflecting data from many epidemiological studies that describe a variable duration of 30-60 min [9, 10, 21] . BTP duration has been reported to be longer in spontaneous unpredictable BTP than in patients with incident-type BTP [10] . It should be considered that BTP duration in untreated BTP is more difficult for patients to properly assess, and not all patients are able to do so.
To facilitate the patients' orientation, a dichotomous measure was chosen for BTP onset (B10 or [10 min). BTP onset was rapid in 71.7% of patients and slower in 28.3% of patients. Similar values, with a median of 10 min, were found in a multicenter European survey [10] and an Italian survey [9] , where they were lower with incident-type BTP. BTP predictability is an important clinical factor with obvious therapeutic consequences for timing and choice of available BTP medications. Moreover, incident-predictable BTP has been considered to be a negative factor for cancer pain management [17, 22, 23] . This is due to the difficulties in balancing analgesia at rest and pain on movement, which often results in attempts to improve basal analgesia with a possible occurrence of opioid-induced adverse effects.
Predictable BTP has a faster onset, typically observed in patients with bone metastases, triggered by physical activity or movement. In this survey, about 35% of patients had predictable BTP, and physical activity was the most frequent trigger. Some factors were independently associated with predictable BTP and included lower Karnofsky index, lower BTP intensity, and faster BTP onset. Predictable BTP has been previously found to be associated with a faster onset of BTP [9, 10] . Pain induced by movement in patients with bone metastases occurs rapidly and is clearly predictable. A worse performance status was associated with predictable BTP. This is in contrast to a previous finding and probably due to the different care setting distribution in the first IOPS study [9] . It is reasonable to hypothesize that patients with a lower Karnofsky index have lower background pain intensity at rest for most daytime hours, but develop predictable BTP on movement. These data should be confirmed in a larger number of patients with complete analysis the IOPS-MS study. Furthermore, the relationship between predictable BTP and BTP intensity is complex.
Patients with a higher BTP intensity had less predictable BTP. This could be explained by patients' attitudes in limiting a sustaining trigger that induced a predictable BTP, thus avoiding a higher peak of pain intensity. Of interest, predictable BTP was more frequently observed in the radiotherapy setting, which could be explained by the fact that patients are commonly referred to these specialists for the treatment of bone metastases. Among the other trigger factors for predictable BTP, swallowing was associated with oral mucositis. Thus, mucosal damage, commonly reported in patients who have received or are still receiving toxic agents [24] , is more likely to produce a predictable BTP on swallowing. As expected, mucositis was associated with head and neck cancer, possibly due to previous anticancer treatment. The presence of mucosal damage was also associated with higher levels of BTP intensity.
Mucositis is a typical example of BTP occurring with swallowing only. Moreover, the presence of oral mucositis has obvious clinical consequences in terms of route of administration when considering the possible use of transmucosal agents such as rapid-onset opioids, prejudicing reliable absorption of oral transmucosal agents [5] . This suggests that physicians should pay more attention to the diagnosis of mucositis, but also to xerostomia and candidiasis, for optimal selection of BTP therapy.
The relationship between background analgesia and BTP intensity is fundamental in describing the phenomenon of BTP, particularly from a therapeutic perspective. It has been reported that a meaningful cutoff of these levels of pain intensity, as reported in the real world by patients instructed in BTP, is about double [12] . In this survey these levels were maintained on average (3 and 7.5 for  background  pain  and  BTP In our survey, a large number of patients were receiving opioids for the management of BTP, particularly transmucosal fentanyl, in relatively similar or proportional doses, according to the fentanyl availability of different delivery systems. Of interest, a highly significant relationship between the doses of BTP opioid medications and opioid doses for background pain was found. This finding reflects the growing evidence suggesting that a dose proportional to the basal opioid regimen is both safe and effective [25] [26] [27] [28] , regardless of recommendations suggesting titrating the dose against the effect [29] . Moreover, adverse reactions attributed to BTP medications were limited and of mild intensity in most cases, and were independent of the drug and dose used.
This observation confirms that opioid medications given in doses proportional to background opioid dose are relatively safe [25, 26] . This aspect deserves further analysis.
Nasal administration of fentanyl provided faster analgesia relative to other fentanyl products [30] . Patient-reported satisfaction with pain treatment is an important outcome measure when assessing both background pain and BTP [8] . Of interest, the use of FPNS and IV-M, home care assessment, pain therapy setting, and the absence of anticancer treatment were associated with the highest level of satisfaction. Therefore, faster analgesia and patients' satisfaction should be strongly considered in order to prescribe optimal treatment. These aspects deserve further research and will be better explored with the complete data of IOPS-MS. There are some limitations to this survey, mainly due to the inherit nature of the study design. Firstly, caution must be taken when interpreting some of the outcomes because of the retrospective nature of the survey.
Furthermore, for some outcomes, data are missing.
CONCLUSIONS
Overall, the number of patients allows a preliminary analysis only. Although preliminary, these data provide interesting information that will be developed with the complete IOPS-MS 
